Study finds new HIV drug lessens side effects vs. current treatment

New study shows latest HIV therapy’s effectiveness
New study shows latest HIV therapy’s effectiveness

Merck scientists recently released data from their latest study on their new HIV therapy, Doravirine (MK 1439).

The Phase 2b study lasted 48 weeks and tested the safety and effectiveness of the new treatment.

None of the patients involved in the study had experienced any previous HIV treatments. The treatment is an oral medicine that is taken once a day.

On week eight of the study, Doravirine had positive results. Patients taking Doravirine experienced reduced side effects to their central nervous systems than did patients taking Efavirenz with TDF/FTC. The most prevalent side effects were dizziness, insomnia, abnormal dreams and nightmares. Doravirine patients showed overall improvement at the end of the 48 weeks.

“This program underscores Merck’s ongoing commitment to the research and development of new therapeutic options for patients with HIV,” Dr. Hedy Teppler, exective director of Infectious Diseases at Merck Research Laboratories, said. “We are encouraged by the antiviral activity and the overall tolerability profile of Doravirine and look forward to initiating Phase 3 studies.”

The results were presented at the 12th International Congress on HIV Drug Therapy, which was held in Glasgow, Scotland, this week.

Organizations in this Story


Want to get notified whenever we write about Merck ?
Next time we write about Merck, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.